Title : Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series.

Pub. Date : 2020

PMID : 33194747






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Patients 2 and 3 showed some response to combined FLT3-inhibitor and BCR-ABL targeted therapy (gilteritinib and ponatinib). ponatinib fms related receptor tyrosine kinase 3 Homo sapiens